USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: 20/20 GENESYSTEMS, INC.
City: ROCKVILLE
State: MD
Zip+4: 20850-6347
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,353,733.00 10
SBIR Phase II $3,399,622.00 2
STTR Phase I $277,279.00 2

Award List:

N/A

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Vladimir Knezevic
Award Amount: $97,435.00

Hair Follicle Assay to Monitor Targeted Cancer Therapy

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Vladimir Knezevic
Award Amount: $96,489.00
Abstract:
DESCRIPTION (provided by applicant): Personalized medicine is a new clinical pardigm where a specific cancer therapeutic is prescribed based upon the individual biology of the patient. For example, specific receptor tyrosine kinase (rTK) inhibitors may be chosen based on the proteomic profile of… More

LAYERED MEMBRANES IN PROTEOMIC PROFILING OF RENAL CANC*

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Vladimir Knezevic
Award Amount: $79,501.00
Abstract:
DESCRIPTION (provided by applicant) "Personalized medicine" is a new clinical paradigm where a specific cancer therapeutic ("smart drug") is prescribed based upon the individual biology of the patient. A goal of personalized medicine is to select individual therapies based upon the correlation of… More

USING NOVEL LAYERED MEMBRANES IN CLINICAL PROTEOMICS

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Vladimir Knezevic
Award Amount: $99,378.00
Abstract:
DESCRIPTION (provided by applicant): Personalized medicine" is a new clinical paradigm where a specific cancer therapeutic ("smart drug") is prescribed based upon the individual biology of the patient. A goal of personalized medicine is to select individual therapies based upon the correlation of… More

LAYERED MEMBRANES IN PROTEIN PROFILING OF BREAST CANCER

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Vladimir Knezevic
Award Amount: $96,387.00
Abstract:
DESCRIPTION (provided by applicant): Personalized medicine" is a new clinical paradigm where a specific cancer therapeutic ("smart drug") is prescribed based upon the correlation of proteomic profiles from diseased tissues with patient's response to drug therapy. Many of these new "smart drug"… More

Smart Membranes for Biomolecular Detection

Award Year / Program / Phase: 2004 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF MARYLAND COLLEGE PK CAMPUS
Principal Investigator: Timothy A. Barbari
Award Amount: $100,000.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The main objective of this project is to develop membranes with surfaces tailored for specific affinity for a particular protein or nucleic acid molecule. These 'smart' membranes will be used in the next generation of high throughput Layered Expression Scanning… More

Auto-antibody profiling of non-small cell lung cancer

Award Year / Program / Phase: 2006 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF KENTUCKY
Principal Investigator: Edward A. Hirschowitz
Award Amount: $177,279.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Tumor markers, measured in peripheral blood, could assist in diagnosis and management of non-small cell lung cancer (NSCLC) and potentially improve historically dismal outcomes. Circulating antibodies, generated to a wide range of tumor-associated proteins, can… More

Profiling EGFR and Her2 in Breast Cancer using Multiplex Tissue Immunostaining

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: William M. James
Award Amount: $117,930.00
Abstract:
DESCRIPTION (provided by applicant): We propose to develop a novel method and kit for profiling the expression and activation of signal transduction proteins in breast tumors. The goal is to create new companion diagnostics to better select patients like ly to respond to targeted therapies,… More

Peptide Array for Profiling of Autoantibodies in Non-small Cell Lung Cancer

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nada H. Khattar
Award Amount: $165,288.00
Abstract:
DESCRIPTION (provided by applicant): Approximately 135,000 new cases of non-small cell lung cancer (NSCLC) are diagnosed each year in the USA, yet only 20%-25% of those patients will be diagnosed at a sufficiently early stage to be cured by surgical or oth er procedures. When used in concert with… More

PredicTOR: predicting patient response to mTOR pathway inhibitors prior to treatm

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: William M. James
Award Amount: $649,622.00
Abstract:
DESCRIPTION (provided by applicant): We propose to develop a novel method and kit for profiling the expression and activation of signal transduction proteins in breast tumors. The goal is to create new companion diagnostics to better select patients like ly to respond to targeted therapies,… More

Autoantibody Profiling for Serological Detection of Head and Neck Cancer

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nada H. Khattar
Award Amount: $217,801.00
Abstract:
DESCRIPTION (provided by applicant): SBIR grant support is being sought by 20/20 GeneSystems, Inc. (20/20), a small biotech company, to help us advance what we believe will become the first blood test to be routinely employed to aid in the early detection of head and neck cancer. Despite recent… More

Profiling Autoantibodies in Non-small Cell Lung Cancer with Fusion Protein-Peptid

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nada H. Khattar
Award Amount: $183,927.00
Abstract:
DESCRIPTION (provided by applicant): Approximately 135,000 new cases of non-small cell lung cancer (NSCLC) are diagnosed each year in the USA, yet only 20%-25% of those patients will be diagnosed at a sufficiently early stage to be cured by surgical or oth er procedures. When used in concert with… More

A COMPANION DIAGNOSTIC FOR PROGNOSIS OF KIDNEY CANCER

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: John Gillespie
Award Amount: $199,597.00
Abstract:
This contract was awarded by the National Cancer Institute's Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) Program under the funding opportunity "Contract Topic: 277 Companion Diagnostics: Predictive and Prognostic Tests Enabling Personalized Medicine… More

PredicTOR: predicting patient response to mTOR pathway inhibitors prior to treatm

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Michael Lebowitz
Award Amount: $2,750,000.00
Abstract:
DESCRIPTION (provided by applicant): The promise of personalized medicine relies on the development of diagnostic tests to categorize patients within small cohorts who will benefit from specific treatments. 20/20 GeneSystems, Inc. (20/20) is a small business concern focused on the development of… More